Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Posters

Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in the PROTECT Open-Label Extension (OLE) Substudy and SPARTACUS: Trials in Progress

Learn More
Posters IgAN

Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy:​ Preliminary Findings From the SPARTAN Trial

Learn More
Posters

Proteinuria and kidney survival in focal segmental​ glomerulosclerosis (FSGS) or immunoglobulin A nephropathy​ (IgAN): A NEPTUNE analysis

Learn More
Posters

Predictors of Major Adverse Kidney Disease Events in a Real-World Population With IgA Nephropathy

Learn More
Posters

The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Focal Segmental Glomerulosclerosis (FSGS) and Immunoglobulin A Nephropathy (IgAN) on Patients and Caregivers Study (HONUS): Results for FSGS in the United States (US)

Learn More
Posters

Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety

Learn More
Posters

A Quantitative Systems Pharmacology (QSP) Model for Classical Homocystinuria Predicting Efficacy of Treatment

Learn More
Posters HCU

Development of a Patient Identification Algorithm to Estimate Prevalence of Classical Homocystinuria (HCU) in the United States (US)

Learn More
Posters HCU

Insights From the First Genetic Evaluation of a Longitudinal Natural History Study in Classical Homocystinuria (HCU)

Learn More
Posters HCU

Population-based Incidence Estimates of Classical Homocystinuria Using the Genome Aggregation Database (gnomAD)

Learn More
Posters

Skeletal Fragility In A Natural History Study Of Homocystinuria Due To Cystathionine Beta-synthase Deficiency Patients

Learn More
Posters

Comorbid Diagnoses, Medications, and Healthcare Provider Types among Patients Diagnosed with Classical Homocystinuria

Learn More
Posters

Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)

Learn More